

# Contents to Volumes 1, 3 and 4

## Volume 1

### Part I Methodological and Technological Advances

- 1 Where Do We Stand in the Quest for Neuropsychiatric Biomarkers and Endophenotypes and What Next?**  
Michael S. Ritsner and Irving I. Gottesman
- 2 Methodological and Statistical Issues in the Use of Biomarkers in Clinical and Research Studies**  
Ryan J. Van Lieshout and Peter Szatmari
- 3 Challenging the Genetic Complexity of Schizophrenia by Use of Intermediate Phenotypes**  
Assen Jablensky
- 4 Translational Medicine: Functional Biomarkers for Drug Development of “Cognitive Enhancers” in Schizophrenia**  
Georg Winterer
- 5 Leveraging High-Dimensional Neuroimaging Data in Genetic Studies of Neuropsychiatric Disease**  
Cinnamon S. Bloss, Trygve E. Bakken, Alexander H. Joyner, and Nicholas J. Schork
- 6 Proteomics as a New Tool for Biomarker-Discovery in Neuropsychiatric Disorders**  
Thomas J. Raedler, Harald Mischak, Holger Jahn, and Klaus Wiedemann
- 7 Schizophrenia Endophenotypes as Treatment Targets**  
Stephen I. Deutsch, Barbara L. Schwartz, Richard B. Rosse, John Mastropaolo, Ayman H. Fanous, Abraham Weizman, Jessica A. Burket, and Brooke L. Gaskins

**Part II Neuropsychological, Neurocognitive and Neurophysiological Domains**

- 8 Neuropsychological Endophenotypes in Schizophrenia and Bipolar I Disorder: Yields from the Finnish Family and Twin Studies**  
Annamari Tuulio-Henriksson, Jonna Perälä, Irving I. Gottesman,  
and Jaana Suvisaari
- 9 Is More Cognitive Experimental Psychopathology of Schizophrenia Really Necessary? Challenges and Opportunities**  
Angus W. MacDonald, III
- 10 Intellectual Functioning as an Endophenotype for Schizophrenia**  
Odette de Wilde
- 11 Emotion Recognition Deficits as a Neurocognitive Marker of Schizophrenia Liability**  
Renata Schoeman, Dana J.H. Niehaus, Liezl Koen,  
and Jukka M. Leppänen
- 12 The Use of Neurocognitive Endophenotypes in Large-Scale Family Genetic Studies of Schizophrenia**  
William P. Horan, Tiffany A. Greenwood, David L. Braff,  
Raquel E. Gur, and Michael F. Green
- 13 Neurocognitive Endophenotypes for Bipolar Disorder: Evidence from Case-Control, Family and Twin Studies**  
Eugenia Kravariti, Fergus Kane, and Robin M. Murray
- 14 Trait and State Markers of Schizophrenia in Visual Processing**  
Yue Chen, Daniel Norton, and Ryan McBain
- 15 Visual Scanning Abnormalities as Biomarker for Schizophrenia**  
Patricia E.G. Bestelmeyer
- 16 Biomarkers and Endophenotypes in Eating Disorders**  
Carolina Lopez, Marion Roberts, and Janet Treasure
- 17 Movement Abnormalities: A Putative Biomarker of Risk for Psychosis**  
Vijay A. Mittal and Elaine F. Walker

**Contents to Volumes 2, 3, and 4**

**Contributors to Volumes 2, 3, and 4**

**Index**

## **Volume 3**

### **Part III Possible Metabolic and Peripheral Biomarkers**

- 28 Peripheral Biomarkers in Dementia and Alzheimer's Disease**  
Christian Humpel and Josef Marksteiner
- 29 S100B as a Potential Neurochemical Biomarker in a Variety of Neurological, Neuropsychiatric and Neurosurgical Disorders**  
Patrick Wainwright, Jon Sen, and Antonio Belli
- 30 Can the Cortisol to DHEA Molar Ratio be Used as a Peripheral Biomarker for Schizophrenia and Mood Disorders?**  
Peter Gallagher and Michael S. Ritsner
- 31 Neuroactive Steroid Biomarkers of Alcohol Sensitivity and Alcoholism Risk**  
A. Leslie Morrow and Patrizia Porcu
- 32 Neuroendocrine Markers of Psychopathy**  
Andrea L. Glenn
- 33 Mitochondrial Complex I as a Possible Novel Peripheral Biomarker for Schizophrenia**  
Dorit Ben-Shachar
- 34 Peripheral Biomarkers of Excitotoxicity in Neurological Diseases**  
Lucio Tremolizzo, Gessica Sala, and Carlo Ferrarese
- 35 Melatonin as a Biological Marker in Schizophrenia**  
Armando L. Morera, Pedro Abreu-Gonzalez, and Manuel Henry
- 36 Peripheral Biological Markers for Mood Disorders**  
Ghanshyam N. Pandey and Yogesh Dwivedi
- 37 The Diagnosis of Alcoholism Through the Identification of Biochemical Markers in Hair**  
Nadia De Giovanni
- 38 Retinoic Acid Signalling in Neuropsychiatric Disease: Possible Markers and Treatment Agents**  
Sarah J. Bailey and Peter J. McCaffery
- 39 Abnormalities of Inositol Metabolism in Lymphocytes as Biomarkers for Bipolar Disorder**  
Galila Agam, Yuly Bersudsky, and Robert H. Belmaker

**Contents to Volumes 1, 2, and 4****Contributors to Volumes 1, 2, and 4****Index****Volume 4****Part IV Molecular Genetic and Genomic Markers**

- 40 Pharmacogenomic Biomarkers in Neuropsychiatry:  
The Path to Personalized Medicine in Mental Disorders**  
Ramón Cacabelos
- 41 Pharmacogenetics in Neurological Diseases**  
Chantal Depondt
- 42 Gene Expression Changes and Potential Impact of Endophenotypes  
in Major Psychiatric Disorders**  
Gursharan Chana, Janet Kwok, Stephen J. Glatt, Ian P. Everall,  
and Ming T. Tsuang
- 43 Molecular Genetics of Schizophrenia: Focus on  
Symptom Dimensions**  
Michael S. Ritsner and Ehud Susser
- 44 Genetics of Mood Disorders**  
Laura Mandelli, Alessandra Nivoli, and Alessandro Serretti
- 45 Endophenotype Strategy in Epilepsy Genetics**  
Dalila Pinto, Dorothée Kasteleijn-Nolst Trenité, and Dick Lindhout
- 46 Epilepsy, Biomarkers, and Genes**  
Danielle M. Andrade
- 47 Molecular and Imaging Genetic Markers  
in Panic Disorder**  
Katharina Domschke and Jürgen Deckert
- 48 The Genetics of Obsessive–Compulsive Disorder**  
Marco A. Grados and Rebecca Dang
- 49 Development of Biomarkers for Alcoholism and Polysubstance Abuse**  
Hiroki Ishiguro, Minori Koga, Yasue Horiuchi, Emmanuel S. Onaivi,  
and Susumu Higuchi

**50 Role of Members of the *Nur* (NR4A) Transcription Factors  
in Dopamine-Related Neurodegenerative and Neuropsychiatric  
Disorders**

Daniel Lévesque and Claude Rouillard

**Contents to Volumes 1, 2, and 3**

**Contributors to Volumes 1, 2, and 3**

**Index**

# Contributors to Volumes 1, 3 and 4

## Volume 1

**Trygve E. Bakken** M.Sc., Scripps Genomic Medicine and Scripps Translational Science Institute; Medical Scientist Training Program and Graduate Program in Neurosciences, University of California, San Diego, CA, USA  
E-mail: tbakken@ucsd.edu

**Patricia E.G. Bestelmeyer**, Ph.D., Post-Doc Centre for Cognitive Neuroimaging  
Department of Psychology, Glasgow, UK  
E-mail: p.bestelmeyer@psy.gla.ac.uk

**Cinnamon S. Bloss**, Ph.D., Research Scientist, Scripps Genomic Medicine and Scripps Translational Science Institute, Scripps Health and The Scripps Research Institute, La Jolla, CA, USA  
E-mail: cbloss@scripps.edu

**David L. Braff**, M.D., Professor, Department of Psychiatry, University of California, San Diego, CA, USA  
E-mail: DBraff@ucsd.edu

**Jessica A. Burket**, B.S., Mental Health Service Line, Department of Veterans Affairs Medical Center, Washington, USA

**Yue Chen**, Ph.D., Director, Visual Psychophysiology Laboratory, McLean Hospital, Department of Psychiatry, Harvard Medical School, Belmont, MA, USA  
E-mail: ychen@mclean.harvard.edu

**Stephen I. Deutsch**, M.D., Ph.D., Mental Health Service Line, Department of Veterans Affairs Medical Center, Washington, Department of Psychiatry, Georgetown University School of Medicine, Washington, USA  
E-mail: Stephen.Deutsch@va.gov

**Ayman H. Fanous**, M.D., Mental Health Service Line, Department of Veterans Affairs Medical Center, Washington, Department of Psychiatry, Georgetown University School of Medicine, Washington, USA

**Brooke L. Gaskins**, B.A., Mental Health Service Line, Department of Veterans Affairs Medical Center, Washington, USA

**Irving I. Gottesman** Professor, Departments of Psychiatry and Psychology,  
University of Minnesota, Minneapolis, MN, USA  
E-mail: gotte003@umn.edu

**Michael F. Green**, Ph.D., Professor, Semel Institute, University of California,  
Los Angeles, CA, USA  
E-mail: mgreen@ucla.edu

**Tiffany A. Greenwood**, Ph.D., Assistant Adjunct Professor of Psychiatry,  
Department of Psychiatry, University of California, San Diego, CA, USA  
E-mail: tgreenwood@ucsd.edu

**Raquel E. Gur**, M.D., Ph.D., The Karl and Linda Rickels Professor and Vice Chair  
for Research Development, Departments of Psychiatry, Neurology and Radiology,  
Director, Neuropsychiatry Section, University of Pennsylvania Medical Center,  
Philadelphia, PA, USA  
E-mail: raquel@upenn.edu

**William P. Horan**, Ph.D., VA Greater Los Angeles Healthcare system &  
University of California, Los Angeles, CA, USA  
E-mail: horan@ucla.edu

**Assen Jablensky**, M.D., D. Med.Sci., Professor of Psychiatry,  
School of Psychiatry and Clinical Neurosciences, The University of Western  
Australia, Director, Centre for Clinical Research in Neuropsychiatry, Australia  
E-mail: assen@cyllene.uwa.edu.au

**Holger Jahn** University of Hamburg, Department of Psychiatry,  
Hamburg, Germany

**Alexander H. Joyner** M.Eng., Scripps Genomic Medicine and Scripps  
Translational Science Institute; Graduate Program in Biomedical Sciences,  
University of California, San Diego, CA, USA  
E-mail: ajoyner@ucsd.edu

**Fergus Kane**, Ph.D. student at the section of General Psychiatry,  
Department of Psychiatry, Institute of Psychiatry, London, UK

**Liezl Koen**, M.B. Ch.B., M.Med. (Psych), Department of Psychiatry,  
University of Stellenbosch, South Africa  
E-mail: liezlk@sun.ac.za

**Eugenia Kravariti**, M.A., M.Sc., Ph.D., Lecturer, NIHR Biomedical Research  
Centre for Mental Health, South London and Maudsley NHS Foundation Trust and  
Institute of Psychiatry, King's College London, UK  
E-mail: e.kravariti@iop.kcl.ac.uk

**Jukka M. Leppänen**, Ph.D., Assistant Professor, Department of Psychology,  
University of Tampere, Tampere, Finland  
E-mail: jukka.leppanen@uta.fi

**Ryan J. Van Lieshout** The Offord Centre for Child Studies, McMaster Children's  
Hospital and Department of Psychiatry and Behavioural Neurosciences, McMaster  
University, Hamilton, Ontario, Canada  
E-mail: rjv@prontomail.com

**Carolina Lopez** Eating Disorders Research Unit, Department of Academic Psychiatry, King's College London, UK  
E-mail: c.lopez@iop.kcl.ac.uk

**Angus W. MacDonald, III**, Ph.D., Associate Professor, Departments of Psychology and Psychiatry, University of Minnesota, Minneapolis, Minnesota, USA  
E-mail: angus@umn.edu

**John Mastropaolo**, Ph.D. Mental Health Service Line, Department of Veterans Affairs Medical Center, Washington, USA

**Ryan McBain** McLean Hospital, Belmont, MA, USA

**Harald Mischak** Mosaiques Diagnostics and Therapeutics AG, Hannover, Germany

**Vijay A. Mittal**, Ph.D., Postdoctoral Scholar, Department of Psychology, University of California Los Angeles, USA  
E-mail: vmittal@mednet.ucla.edu

**Robin M. Murray**, Professor of Psychiatry, Institute of Psychiatry, King's College London, UK  
E-mail: robin.murray@iop.kcl.ac.uk

**Dana J.H. Niehaus**, M.B. Ch.B., M.Med. (Psych.), D.Med. (Psych.), FC Psych., Department of Psychiatry, University of Stellenbosch, South Africa  
E-mail: djhn@sun.ac.za

**Daniel Norton** McLean Hospital, Belmont, MA, USA

**Jonna Perälä**, M.D., Researcher, National Public Health Institute, Department of Mental Health and Alcohol Research, Helsinki, Finland  
E-mail: jonna.perala@ktl.fi

**Thomas J. Raedler**, M.D., Associate Professor, Department of Psychiatry, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada  
E-mail: Thomas.Raedler@albertahealthservices.ca;  
Thomas.Raedler@Calgaryhealthregion.ca

**Michael S. Ritsner**, M.D., Ph.D., Associate Professor of Psychiatry and Head of Cognitive and Psychobiology Research Laboratory, The Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa and Chair, Acute Department, Sha'ar Menashe Mental Health Center, Hadera, Israel  
E-mail: ritsner@sm.health.gov.il

**Marion Roberts**, Eating Disorders Research Unit, Department of Academic Psychiatry, Institute of Psychiatry, King's College London, 5th Floor Bermondsey Wing, Guy's Hospital, London, SE1 9RT ddi. 0207 188 0181  
E-mail: marion.roberts@iop.kcl.ac.uk; www.eatingresearch.com

**Richard B. Rosse**, M.D., Mental Health Service Line, Department of Veterans Affairs Medical Center, Washington, Department of Psychiatry, Georgetown University School of Medicine, Washington, USA

**Renata Schoeman**, M.B. Ch.B., M.Soc. Sc., M.Med. (Psych.), FC Psych., Department of Psychiatry, University of Stellenbosch, South Africa  
E-mail: bibitica@mweb.co.za

**Nicholas J. Schork**, Ph.D., Director of Research, Scripps Genomic Medicine; Director of Biostatistics and Bioinformatics, The Scripps Translational Science Institute; Professor, Molecular and Experimental Medicine, Scripps Health and The Scripps Research Institute, CA, USA  
E-mail: nschork@scripps.edu

**Barbara L. Schwartz**, Ph.D., Mental Health Service Line, Department of Veterans Affairs Medical Center, Washington, Department of Psychiatry, Georgetown University School of Medicine, Washington, USA

**Jaana Suvisaari**, M.D., Ph.D., Academy research fellow, National Public Health Institute Department of Mental Health and Alcohol Research, Helsinki, Finland  
E-mail: jaana.suvisaari@ktl.fi

**Peter Szatmari** Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada  
E-mail: szatmar@mcmaster.ca

**Janet Treasure** Psychological Medicine Department, King's College London, Institute of Psychiatry, London, UK  
E-mail: Janet.Treasure@iop.kcl.ac.uk

**Annamari Tuulio-Henriksson**, Ph.D., Senior Researcher, National Public Health Institute Department of Mental Health and Alcohol Research, Helsinki, Finland  
E-mail: annamari.tuulio-henriksson@ktl.fi

**Elaine F. Walker**, Ph.D., Samuel Candler Dobbs Professor of Psychology and Neuroscience, Department of Psychology, Emory University, USA  
E-mail: psyefw@emory.edu

**Abraham Weizman**, M.D., Professor of Psychiatry, Research Unit, Geha Mental Health Center and the Laboratory of Biological Psychiatry at Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Tel-Aviv  
E-mail: Israel.aweizman@clalit.org.il

**Klaus Wiedemann** University of Hamburg, Department of Psychiatry, Hamburg, Germany

**Odetta de Wilde**, Ph.D., Academic Medical Center, University of Amsterdam, Department of Psychiatry, The Netherlands  
E-mail: o.dewilde@amc.uva.nl

**Georg Winterer**, M.D., Ph.D., Associate Professor, Department of Psychiatry, Heinrich-Heine University, Duesseldorf, and Institute of Neurosciences and Biophysics, Juelich Research Centre, Juelich, Germany  
E-mail: georg.winterer@uni-duesseldorf.de

### Volume 3

**Pedro Abreu-Gonzalez** Professor of Biochemistry, Department of Physiology, School of Medicine, University of La Laguna, La Laguna, Santa Cruz de Tenerife, Canary Islands, Spain

**Galila Agam**, Ph.D., Associate Professor, Psychiatry Research Unit and Department of Clinical Biochemistry, Faculty of Medicine, Ben Gurion University, Israel

**Sarah J. Bailey** Lecturer, Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, UK  
E-mail: S.Bailey@bath.ac.uk

**Dorit Ben-Shachar**, Ph.D., Head of Lab, Laboratory of Psychobiology, Department of psychiatry, B. Rappaport Faculty of Medicine, Rambam Medical Center, Technion IIT, Haifa, Israel  
E-mail: shachar@tx.technion.ac.il

**Yuly Bersudsky**, M.D., Ph.D., Senior Lecturer, Faculty of Medicine, Ben Gurion University, Beersheva Mental Health Center, Beersheva, Israel

**Yogesh Dwivedi**, Ph.D., Associate Professor, University of Illinois at Chicago, Department of Psychiatry, Chicago, IL, USA  
E-mail: ydwivedi@psych.uic.edu

**Carlo Ferrarese**, M.D., Ph.D., Professor of Neurology, Director of the Department of Neurology and of the Neurology Residency School, University of Milano-Bicocca, Ospedale San Gerardo, Monza, Italy  
E-mail: carlo.ferrarese@unimib.it

**Peter Gallagher** Research Associate in Psychiatry, School of Neurology, Neurobiology and Psychiatry, Newcastle University, Leazes Wing (Psychiatry), Newcastle upon Tyne, UK  
E-mail: peter.gallagher@ncl.ac.uk

**Nadia De Giovanni** Istituto Medicina Legale, Università Cattolica S. Cuore, Roma, Italy  
E-mail: nadia.degiovanni@rm.unicatt.it

**Andrea L. Glenn**, M.A., Doctoral Student, University of Pennsylvania, Philadelphia, PA, USA  
E-mail: aglenn@sas.upenn.edu

**Manuel Henry** Professor of Psychiatry, Department of Internal Medicine, Dermatology and Psychiatry, School of Medicine, University of La Laguna, La Laguna, Santa Cruz de Tenerife, Canary Islands, Spain

**Christian Humpel** Associate Professor Dr., Laboratory of Psychiatry and Exp. Alzheimer's Research, Department of General Psychiatry, Innsbruck Medical University, Innsbruck, Austria  
E-mail: christian.humpel@i-med.ac.at

**Josef Marksteiner**, M.D., Associate Professor Dr., Laboratory of Psychiatry and Exp. Alzheimer's Research, Department of General Psychiatry, Innsbruck Medical University, Innsbruck, Austria  
E-mail: J.Marksteiner@i-med.ac.at

**Peter McCaffery** Professor, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen, UK  
E-mail: p.j.mccaffery@abdn.ac.uk

**Armando L. Morera** Professor of Psychiatry, Department of Internal Medicine, Dermatology and Psychiatry, School of Medicine, University of La Laguna, La Laguna, Santa Cruz de Tenerife, Canary Islands, Spain  
E-mail: amorera@ull.es

**A. Leslie Morrow**, Ph.D., Professor of Psychiatry and Pharmacology, Associate Director, Bowles Center for Alcohol Studies, University of North Carolina School of Medicine, USA  
E-mail: morrow@med.unc.edu

**Ghanshyam N. Pandey**, Ph.D., Professor, University of Illinois at Chicago, Department of Psychiatry, Chicago, IL, USA  
E-mail: gpandey@psych.uic.edu

**Patrizia Porcu** Assistant Professor of Psychiatry, Bowles Center for Alcohol Studies, University of North Carolina School of Medicine, USA  
E-mail: patrizia\_porcu@med.unc.edu

**Michael S. Ritsner**, M.D., Ph.D., Associate Professor of Psychiatry and Head of Cognitive and Psychobiology Research Laboratory, The Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa and Chair, Acute Department, Sha'ar Menashe Mental Health Center, Hadera, Israel  
E-mail: ritsner@sm.health.gov.il

**Gessica Sala**, Ph.D., Post-doctoral Research Associate, Department of Neuroscience and Biomedical Technologies, University of Milano-Bicocca, Italy  
E-mail: gessica.sala@unimib.it

**Jon Sen** Specialty Registrar in Neurosurgery; Wessex Neurological Centre, Southampton University Hospitals, UK  
E-mail: jsen@ion.ucl.ac.uk

**Lucio Tremolizzo**, M.D., Ph.D., Neurologist and Post-doctoral Research Associate, University of Milano-Bicocca; Ospedale San Gerardo, Monza, Italy  
E-mail: lucio.tremolizzo@unimib.it

## Volume 4

**Danielle M. Andrade**, M.D., M.Sc., Assistant Professor, Department of Medicine, University of Toronto, Division of Neurology – Epilepsy Program UHN – Toronto, Western Hospital, Toronto, Canada  
E-mail: Danielle.Andrade@uhn.on.ca

**Ramón Cacabelos** Professor and Chairman EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, EuroEspes Chair of Biotechnology and Genomics, Camilo José Cela University, Coruña, Spain  
E-mail: rcacabelos@euroespes.com

**Gursharan Chana**, Ph.D., Department of Psychiatry, University of California, San Diego, La Jolla, CA, 92093-0603, USA

**Rebecca Dang** Johns Hopkins University, Baltimore, MD, USA

**Juergen Deckert**, M.D., Full Professor and Chairman, Department of Psychiatry, University of Wuerzburg, Germany  
E-mail: Deckert\_J@klinik.uni-wuerzburg.de

**Chantal Depondt**, M.D., Ph.D., Department of Neurology, Hôpital Erasme, Université Libre de Bruxelles, Belgium  
E-mail: cdepondt@ulb.ac.be

**Katharina Domschke**, M.D., M.A., Head of Group “Genetics of Affective Disorders”, Department of Psychiatry, University of Muenster, Germany  
E-mail: katharina.domschke@ukmuenster.de

**Ian P. Everall**, M.D., Ph.D, FRCPsych., FRCPath., Department Of Psychiatry, University of California, San Diego, CA, USA

**Stephen J. Glatt**, Ph.D., Department of Psychiatry and Behavioral Sciences, State University of New York, Syracuse, NY 13210, USA

**Marco A. Grados**, M.D., M.P.H., Assistant Professor, Johns Hopkins University School of Medicine, Baltimore, MD, USA  
E-mail: mjgrados@jhmi.edu

**Susumu Higuchi**, M.D., Ph.D., National Hospital Organization, Kurihama Alcoholism Center, Kanagawa, Japan  
E-mail: h-susumu@db3.so-net.ne.jp

**Yasue Horiuchi**, Ph.D., Department of Medical Genetics, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan  
E-mail: yasuhoriuchi06@ob.md.tsukuba.ac.jp

**Hiroki Ishiguro**, M.D., Ph.D., Assistant Professor of Department of Medical Genetics, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan  
E-mail: hishigur@md.tsukuba.ac.jp

**Dorothee Kasteleijn-Nolst Trenité** Professor Medical Genetics, University of Utrecht; Department of Medical Genetics, University Medical Centre, Utrecht, the Netherlands; Professor Neuroscience, University of Rome “Sapienza”, Department of Neuroscience, Rome, Italy  
E-mail: Dorothee.Kasteleijn@uniroma1.it; D.kasteleijn@umcutrecht.nl

**Minori Koga**, Ph.D., Department of Medical Genetics, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan  
E-mail: taq-pol@tmail.plala.or.jp

**Janet Kwok**, B.Sc., Department Of Psychiatry, University of California, San Diego, La Jolla, CA, 92093-0603, USA

**Daniel Lévesque** Associate Professor, Senior Scientist, Faculty of Pharmacy University of Montreal, Canada  
E-mail: daniel.levesque.1@umontreal.ca

**Dick Lindhout** Department of Medical Genetics, University Medical Centre Utrecht, Utrecht, The Netherlands

**Laura Mandelli**, Psy.D., Assistant Professor of Psychiatry, Institute of Psychiatry, University of Bologna, Italy  
E-mail: laura.mandelli@unibo.it

**Alessandra Nivoli**, M.D., Associate Professor of Psychiatry, Institute of Psychiatry, University of Sassari, Via Luna e Sole 55, 07100, Sassari, Italy  
E-mail: alessandro.serretti@unibo.it

**Emmanuel S. Onaivi**, Ph.D., Associate Professor of Department of Biology, William Paterson University, Wayne, NJ, USA  
E-mail: OnaiviE@wpunj.edu

**Dalila Pinto**, Ph.D., Research Fellow. Department of Medical Genetics. University Medical Center Utrecht, Utrecht, the Netherlands; and Genetics and Genome Biology, The Center for Applied Genetics, The Hospital of Sick Children, Toronto, Canada.  
E-mail: d.c.s.pinto@gmail.com

**Michael S. Ritsner**, M.D., Ph.D., Associate Professor of Psychiatry and Head of Cognitive and Psychobiology Research Laboratory, The Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa and Chair, Acute Department, Sha’ar Menashe Mental Health Center, Hadera, Israel  
E-mail: ritsner@sm.health.gov.il

**Claude Rouillard**, Ph.D., Professor, Department of Medicine, Faculty of Medicine, Laval University and Neuroscience Research Centre, Laval University Hospital Research Centre, Québec City, Québec, Canada  
E-mail: clauderouillard@neurosciences.ulaval.ca

**Alessandro Serretti**, M.D., Associate Professor of Psychiatry, Institute of Psychiatry, University of Bologna, Italy  
E-mail: alessandro.serretti@unibo.it

**Ehud Susser**, M.D., Senior Psychiatrist, Sha’ar Menashe Mental Health Center, Hadera, and the Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel  
E-mail: udiwudi@yahoo.com

**Ming T. Tsuang**, M.D., Ph.D., D.Sc., Behavioral Genomics Endowed Chair and University Professor, University of California; Distinguished Professor of Psychiatry and Director, Center for Behavioral Genomics, Department of Psychiatry, University of California, San Diego, CA; Director, Harvard Institute of Psychiatric Epidemiology and Genetics, Harvard Medical School and Harvard School of Public Health, USA  
E-mail: mtsuang@ucsd.edu

# Index

## A

Adenine triphosphate (ATP), 171, 183  
Alzheimer's disease, 3–11, 17, 21, 23, 26, 30–32, 34–38, 40, 61, 94, 113, 194, 185, 188, 189, 227  
Amygdala-Hippocampal Complex (AHC), 87, 92, 112, 220  
Amyotrophic lateral sclerosis (ALS), 201, 208  
Antipsychotic agents, 130  
Antisaccade task, 72, 75, 77  
Antipsychotics, 106–108, 134, 135, 171, 192  
Anxiety, 21, 29, 133, 160, 172, 203, 216  
Apolipoprotein E (APOE), 3, 5, 10  
Attention, 22, 25, 29, 34, 37, 43, 44, 59, 61, 68, 74, 76, 98, 100, 104, 109, 123, 128, 131, 132, 135, 145, 146, 148, 154, 155, 160, 162, 171, 172, 175, 180, 189, 202, 203, 208, 216, 217  
Attentional Deficit Hyperactive Disorder (ADHD), 145–147, 155, 160, 171, 172, 176, 177, 180, 181, 189–191  
Autism, 145–163, 176

## B

Basal Ganglia, 33, 36, 37, 40, 75, 76, 87, 88, 90, 92, 1061–08, 113, 125, 151, 158, 175, 179, 183, 185–187, 189, 192, 203, 208, 210  
Behavioral markers, 162  
Biomarker, 3–11, 17, 18, 28, 30, 32, 33, 36, 37, 40, 41, 56, 58, 59, 61, 63, 64, 123–136, 171–192, 201, 202, 205, 207, 209, 210, 216, 227–229  
Bipolar disorder, 59, 64, 74, 77, 79, 88, 171–192, 227–229  
Brain, 4–11, 17–32, 34, 35, 37, 38, 40–45, 55, 57–62, 70, 71, 78, 87–91, 93–95, 97–102, 104–114, 123–127, 130–136, 145–163, 172–175, 177–179, 181–183, 186–188, 191, 192, 201–203, 205, 205, 207–209, 215–222, 227, 228  
Brain Derived Neurotrophic Factor (BDNF), 67, 73, 78, 126, 135, 161, 214, 222  
Brief Psychiatric Rating Scale (BPRS), 99

## C

Cambridge Neuropsychological Test Automated Battery (CANTAB), 215, 218  
Catechol-O-methyltransferase (COMT), 55, 61, 67, 71, 73–77, 123, 132–135, 215, 219, 221, 222  
Central nervous system (CNS), 17–19, 41, 69, 125, 132, 153, 163  
Cerebral spinal fluid (CSF), 5, 7, 18, 24, 42, 87, 94, 95, 111, 112, 126, 127, 174, 201, 208–210  
Cingulate Gyrus (CG), 7, 87, 94, 95, 103, 104, 130, 132  
Cognition, 10, 25, 27, 31, 33, 34, 37, 40, 43, 44, 55, 59–62, 64, 102, 106, 134, 155, 157, 162, 174, 215, 220

Cognitive behavioral therapy (CBT), 201, 204, 207  
Cognitive endophenotypes, 216, 229  
Computer Tomography (CT), 18, 21, 24, 37, 55, 67, 69, 87, 111, 215, 216  
Comorbidity, 181  
Continuous Performance Test (CPT), 128, 131, 132  
Corpus Callosum (CC), 87, 96, 97, 110, 111, 126, 158, 159, 185

## D

D-amino-acid oxidase activator (G72 or DAOA), 67, 73, 74, 135  
Dementia, 3, 4, 6, 9, 17, 18, 21–23, 25–27, 29–32, 34, 37–41, 56, 60, 61, 78, 124, 149  
Demyelinating disease, 17–20, 23, 41, 42, 45, 173  
Depression, 23, 26, 29–31, 34, 38, 41, 100, 133, 171, 175, 181, 183, 186, 187, 189, 190, 202, 203, 205, 206, 215, 219  
Diagnostic markers, 61, 67, 69, 70, 79  
Disrupted in Schizophrenia 1 (DISC1), 75, 123, 126, 135  
Dizygotic twins (DZ), 87, 111, 151  
DNA-Deoxyribonucleic acid, 67, 78, 151, 157, 163, 229  
Dopamine (DA), 18  
Dopamine receptor D2 (DRD2), 106, 133  
Dopamine receptor D3 (DRD3), 135  
Dopaminergic neurotransmission, 69, 70, 73, 76, 123, 124, 131, 134  
Dorsolateral Prefrontal Cortex (DLPFC), 33, 35, 55, 61, 74, 78, 123, 127–129, 131, 132, 157, 175, 179–181, 183–190, 201, 203, 206, 220  
Dysbindin (DTNBP1), 71, 73–75

## E

Electroencephalography, 55  
Endophenotypes, 67–79, 87–114, 145–163, 216, 227, 229, 230  
Endophenotype strategy, 227, 229  
Environment, 70, 78, 132, 133, 147  
Epigenetic, 125, 229  
Epilepsy, 59, 77, 88, 147, 229  
Event-related potentials (ERP), 55, 62, 63, 67, 70–73, 75, P300, 62, 67, 70–73, 75, 78, 79, 220  
Eye tracking movements, 69, 74

## F

Functional Magnetic Resonance Imaging (fMRI), 3, 5, 8, 11, 18, 20, 32, 36, 37, 40, 41, 55, 58, 59, 61–63, 67, 70, 72, 73, 75, 77, 123, 127, 130–132, 134–136, 171, 172, 177–181, 191, 201, 203, 215, 216, 220

**G**

Gamma-amino-butyric acid (GABA), 68, 72, 73, 76, 171, 182–185, 187, 189, 190, 201, 208  
 Genetics, 30, 59, 69, 78, 88, 123, 132, 134, 149, 152, 154, 156, 158, 201, 207, 209, 210, 229  
 Genetic marker, 57, 59  
 Genome Wide Association (GWA), 72  
 Genomics, 149  
 Glucocorticoid Receptor (GR), 67  
 Glutamate, 19, 55, 61, 68, 73, 74, 171, 182, 183, 185, 187, 189, 190, 201–210  
 Glutamatergic neurotransmission, 72, 74  
 Gray Matter (GM), 6, 17–19, 23, 27, 30, 37–39, 42, 44, 87–95, 97, 98, 101–106, 109, 123, 125–127, 130, 131, 135, 173, 174, 176, 177, 183, 185–187, 189, 203, 209

**H**

Hallucinations, 18, 31, 32, 34, 37, 38, 55–59, 76, 99–102, 105, 107, 109, 113, 128, 130  
 Hamilton Depression Rating Scale (HDRS), 215, 219  
 Heritability, 56, 89, 113, 125, 146, 147, 150, 151, 158, 207, 228  
 Hippocampus, 4, 7, 8, 36, 37, 40, 58, 59, 73, 75, 78, 87, 88, 90–93, 98–100, 106, 108, 111, 113, 123, 125, 176, 177, 183, 175–187, 192, 203, 208, 215–221  
 Hormone, 229  
 Hypofrontality, 59, 60, 72, 131

**I**

Inositol, 171, 182, 189  
 Imaging genetics, 123, 132, 134, 149, 152, 154, 156, 158, 210

**L**

Learning, 31, 36, 42, 45, 98, 146, 147, 157, 160, 215, 216, 218  
 Limbic-hypothalamic-pituitary-adrenal (LHPA), 202, 205  
 Lithium (Li), 171, 175, 176, 182–192

**M**

Magnetoencephalography (MEG), 55, 62  
 Magnetic resonance imaging (MRI), 3–11, 17–25, 27–30, 37, 38, 41–45, 55, 57, 59, 68, 71, 75, 87–89, 94, 96–98, 101, 102, 105, 106, 108–113, 123–136, 145, 150, 152, 154, 155, 157, 171–174, 191, 192, 202, 203, 205, 209, 210, 215, 216, 219  
 Magnetic resonance spectroscopy (MRS), 3, 5, 7, 17–198, 23, 28, 40, 44, 45, 71–74, 123, 171, 172, 182–184, 186–188, 191, 201–203, 205, 209, 220  
 Magnetoencephalography (MEG), 3, 55, 62  
 Major depression, 100, 202, 205, 206, 219  
 Memory, 8, 10, 27, 29, 31, 36, 37, 40, 42–45, 55, 56, 58–62, 67, 71–76, 98–100, 105, 106, 108, 113, 123, 129, 131–136, 155, 157, 178–181, 216, 218–220  
 Metabolomics, 19, 20, 33, 35, 36, 40, 41, 55, 124, 174  
 Mismatch negativity (MMN), 67, 68, 72, 73, 75, 76, 79, 128  
 Mitochondria, 182  
 Monozygotic twins (MZ), 76, 78, 87, 99, 111, 123, 126, 150, 151, 154, 155, 157, 158  
 Mood disorders, 21, 23, 59, 174, 175, 177, 220

Movement abnormalities, 229  
 Multiple sclerosis, 18, 19, 41–45

**N**

N-acetyl-aspartate (NAA), 7, 18, 19, 28, 40, 44, 73, 123, 135, 171, 182–185, 188–191, 202–206  
 Neural network, 61, 127, 130, 191  
 Neuregulin-1(NRG1), 77, 123, 135  
 Neurochemistry, 36, 227  
 Neurodegenerative disorder, 17, 21, 27, 28, 30, 32, 37, 125  
 Neurodevelopment, 88, 125  
 Neuron, 23, 57, 125, 127, 131, 134, 157, 182, 208  
 Neuropathology, 45  
 Neurophysiology, 55, 58, 62–64  
 Neurophysiological endophenotypes, 71, 79  
 Neuroprotection, 70  
 Neuropsychiatric disorders, 60, 62, 94, 201, 202, 210, 216, 222  
 Neuroscience, 21, 55, 58, 63, 88, 124, 131, 136  
 Neurosteroid, 134  
 Neurostructural Endophenotype (NSEP), 145–164  
 Nicotinic acetylcholine receptor (nAChR), 77  
 N-methyl-D-aspartate (NMDA), 201, 202, 208

**O**

Obsessive-Compulsive Disorder (OCD), 77, 201–210

**P**

Parkinson's disease, 17, 18, 30–41, 43  
 Peripheral markers, 209, 227  
 Personality, 56, 87, 88, 98, 100–106, 108–113, 123, 220  
 Phenotype, 37, 64, 87, 89, 112, 132–145, 147–155, 157, 158, 160–163, 176, 230  
 Phenotypic variation, 229  
 Plasticity, 17, 78, 123, 124, 208  
 Polymorphism, 67, 74–76, 123, 133, 134, 145, 152–155, 158, 161, 208, 209, 219  
 Positive and Negative Syndrome Scale (PANSS), 55, 57, 59  
 Positron emission tomography (PET), 3–11, 17, 18, 20, 21, 28, 29, 32–37, 40, 41, 55, 59, 70, 73, 123, 124, 135, 171, 177, 215, 216  
 Prefrontal cortex (PFC), 87, 102, 103, 123, 126–129, 131–135  
 Prepulse Inhibition (PPI), 68, 71, 77, 135  
 Prognostic markers, 40  
 Proteomics, 227

**R**

Regulator of G protein signaling 4 (RGS4), 123, 135  
 Rey Auditory Verbal Learning (RAVLT), 215, 218–220  
 Ribonucleic acid (RNA), 68, 70, 76

**S**

Second-generation antipsychotic agents (SGAs), 135  
 Selective serotonin reuptake inhibitor (SSRI), 188, 189, 201, 202, 204, 207, 208  
 Seizures, 42, 59  
 Serotonergic neurotransmission, 69

- Serotonin (5-HT), 31, 34, 41, 133, 145, 154, 161, 169, 201, 208
- Scale for the Assessment of Positive (Psychotic) Symptoms (SAPS), 87, 109, 215, 219, 221
- Scale for the Assessment of Negative (Psychotic) Symptoms (SANS), 87, 109, 215, 221
- Schizophrenia, 55–64, 67–79, 87–114, 123–136, 145, 146, 174, 175, 215, 216, 219–222, 227–229
- Schizotypal Personality Disorder (SPD), 87–89, 98, 100–106, 108–113, 123, 126
- Side effects, 69, 76, 134, 188
- Single Nucleotide Polymorphisms (SNPs), 123, 133, 135, 145, 153
- Single photon emission computed tomography (SPECT), 3, 5, 7, 10, 17, 18, 20, 21, 28–30, 32–36, 41, 55, 59, 171, 177
- Social cognition, 55, 59, 61, 62, 64, 155, 162
- State marker, 58, 67, 70, 79
- Stress, 68, 69, 148, 222
- Striatum, 9, 36, 126, 128, 133–135, 179, 201, 203, 205, 208, 220
- Stroke, 18, 21–23, 26–28
- Structured Clinical Interview for DSM Disorders (SCID), 87, 99, 109
- Suicide, 172
- Suppression of P50, 161
- Synapse, 73, 78, 203, 215
- Symptoms, 17, 21, 26, 27, 29–36, 38, 40–42, 55–59, 61–64, 67–71, 75, 76, 79, 87, 88, 98–105, 112, 113, 124–126, 130–132, 134, 145, 147, 151–153, 155–158, 160, 161, 163, 172, 179, 181, 186, 187, 190, 201, 203, 205, 207, 208, 215–222
- Symptom dimensions, 220
- T**
- Temporal lobe epilepsy, 59, 88
- Testosterone, 208
- Thalamus, 7, 26, 29, 33, 34, 37, 44, 87, 88, 90, 104, 105, 108, 109, 113, 125, 127, 151, 157, 175, 179, 181, 185, 187, 189, 201, 203, 205, 207, 217
- The long serotonin transporter promoter region (5-HTTLPR), 133, 145, 154, 155, 158
- Tolerance, 68
- Toxicity, 41, 188, 220
- Trait marker, 55, 58, 59, 67, 70, 77, 127, 131, 177
- Transcranial magnetic stimulation, 58, 68, 71, 73, 74, 76, 229
- Translin-associated factor X gene (TRAX), 123, 135
- U**
- ultra-high-risk (UHR), 68, 219
- V**
- Verbal memory, 44, 99, 100, 108, 113
- Variable number of tandem repeat (VNTR), 133, 145, 155
- Vascular dementia (VaD), 17, 18, 21–30
- Voxel based morphometry (VBM), 3, 5, 6, 10, 18, 32, 37, 87, 88, 105, 123, 125, 126, 130, 135, 155, 171, 173, 176, 177, 203, 209, 210, 215–217
- W**
- Wisconsin Card Sorting Test (WCST), 73, 75, 76, 129
- Working Memory, 31, 36, 37, 42, 45, 55, 60–62, 67, 71, 73–76, 108, 123, 129, 131–136, 157, 178–181